CRL250516C180000
- 0.15
- 0.000.00%
Charles River Newsroom
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Vanda Claims FDA 'Unlawfully' Delays Hearing Request on Tradipitant Decision
9 Health Care Stocks With Whale Alerts In Today's Session
Humanized Mouse and Rat Model Market Worth US$409.8 Million in 2030 With 8.2% CAGR | MarketsandMarkets
Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break
Charles River Associates (CRA) Strengthens Its Risk, Investigations & Analytics Practice
Research Alert: CFRA Keeps Hold View On Shares Of Charles River Laboratories International Inc.
Express News | Charles River Laboratories International Inc : Jefferies Cuts Target Price to $100 From $169
Notable Healthcare Headlines for the Week: UnitedHealth, Eli Lilly, J&J in Focus
Baird Maintains Charles River(CRL.US) With Hold Rating, Raises Target Price to $118
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
Short Bets Against S&P 500 Healthcare Stock Rises in March; MRNA Stays Top Shorted
Charles River Associates (CRA) to Host First-Quarter Fiscal 2025 Financial Results Conference Call on May 1
Express News | Charles River Laboratories International Inc : Baird Raises Target Price to $118 From $101
Why Investors Shouldn't Be Surprised By Charles River Laboratories International, Inc.'s (NYSE:CRL) 38% Share Price Plunge
Sell-rated S&P 500 Stocks as per Seeking Alpha's Quant Model
Trump Signs Executive Order on Drug Pricing